No profile data available.
Syndax Pharmaceuticals, Inc. (SNDX) is a healthcare company in the organ transfer treatment drugs industry, based in New York, United States, with about 298 full-time employees.
It reported revenue of $172.35 million for fiscal year 2025, up 627.8% from fiscal year 2024, and net income of -$285.42 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $72.79 million, up 91.8% from a year before. Its market capitalization was $1.51 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Syndax Pharmaceuticals reported $172.35 million in revenue for fiscal year 2025, up 627.8% from $23.68 million in fiscal year 2024. In Q2 2026 revenue was $72.79 million.
$1.51 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (organ transfer treatment drugs) include Mesoblast Limited (MESO), Omeros Corporation (OMER), Eledon Pharmaceuticals, Inc. (ELDN), Equillium, Inc. (EQ).